Effectiveness and safety of tacrolimus versus infliximab as rescue therapy for intravenous corticosteroid-refractory acute severe ulcerative colitis: a multicenter cohort study
- 3 September 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (9)
Abstract
Background & Aims: Acute severe ulcerative colitis (ASUC) refractory to intravenous corticosteroids (IVCS) is a major clinical challenge with limited rescue therapy options. Although tacrolimus has been proposed as a potential rescue therapy, its effectiveness and safety compared with infliximab, widely used in this setting, remain unclear. Methods: A multicenter retrospective cohort study was conducted across 34 Japanese institutions, including hospitalized patients with IVCS-refractory ASUC who received infliximab or tacrolimus as rescue therapy between January 2014 and March 2023. The primary outcome was clinical remission at day 14, using two-item patient-reported outcome scoring. Secondary outcomes included clinical response at day 3 and 7, colectomy, and adverse events within 56 days. A modified Poisson regression model was used for analysis. Results: Among 300 patients (infliximab, n = 113; tacrolimus, n = 187), clinical remission at day 14 occurred in 41.6% and 33.7%, respectively, with no difference (adjusted risk ratio [RR] 0.87 [95% CI: 0.65, 1.17]). Clinical response at day 3 was lower with tacrolimus (infliximab 42.5% vs tacrolimus 24.1%; adjusted RR 0.58 [95% CI: 0.42, 0.80]) but did not differ at day 7 (infliximab 63.7% vs tacrolimus 51.9%; adjusted RR 0.83 [95% CI: 0.69, 1.01]). No difference in colectomy within 56 days was observed, although rates were higher in the tacrolimus (13.3% vs 20.3%; adjusted RR 1.58 [95% CI: 0.93, 2.67]). Adverse events were similar between groups (infliximab 8.8% vs tacrolimus 7.5%; adjusted RR 0.77 [95% CI: 0.37, 1.57]). Conclusions: Tacrolimus demonstrated comparable effectiveness and safety to infliximab as rescue therapy for IVCS-refractory ASUC, although early response was slower.Keywords
Funding Information
- Japanese Society for Inflammatory Bowel Disease
This publication has 38 references indexed in Scilit:
- Evidence-based clinical practice guidelines for inflammatory bowel disease 2020Journal of Gastroenterology, 2021
- Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2021
- Estimating Risk Ratios and Risk DifferencesJAMA, 2020
- Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative ColitisDigestive Diseases and Sciences, 2020
- Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic ReviewClinical Gastroenterology and Hepatology, 2018
- Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitisInflammatory Bowel Diseases, 2012
- The pattern and outcome of acute severe colitisJournal of Crohn's and Colitis, 2010
- Colectomy rate in acute severe ulcerative colitis in the infliximab eraDigestive and Liver Disease, 2008
- Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-RegressionClinical Gastroenterology and Hepatology, 2007
- What's the Relative Risk?JAMA, 1998